Literature DB >> 22409952

[Imported diseases by immigrants and travellers: results from the Cooperative Network for the study of Imported Diseases by Immigrants and Travellers +Redivi].

Marta Díaz-Menéndez1, Jose A Pérez-Molina, Nuria Serre, Begoña Treviño, Diego Torrús, Mariano Matarranz, Esteban Martín, Gerardo Rojo-Marcos, Paloma Aguilera, Alicia Rico, Inés Suárez-García, Rogelio López-Vélez.   

Abstract

INTRODUCTION: Imported diseases by travellers and immigrants are a priority in the prevention of emerging infectious diseases in the 21st century. There are international records on imported diseases, but no such records are available in Spain.
MATERIAL AND METHODS: The cooperative network +Redivi was created in 2009 and consists of 11 national healthcare centres. +Redivi collects demographic data relating to travel/migration and infectious diseases in brief, computerised forms.
RESULTS: From January 2009 to October 2011, we collected 4,570 patients and recorded the main demographic data (age, sex, presence of immunosuppression), travel data (destination, duration, time between the return trip and the consultation) and data regarding the migratory process (country of origin, time between the arrival in Spain and the first consultation), as well as preventive measures that have been taken (pre-travel advice, need for malaria chemoprophylaxis, drug that was used and whether it was correct), the reason for coming to the consultation, and final diagnoses of the travellers, immigrants and immigrants-travellers. Likewise, the most frequent diagnoses of asymptomatic patients who came for a check-up are described for each of the three groups.
CONCLUSIONS: The +Redivi network allows us to identify and quantify the geographical origin and the type of patients affected, as well as time pattern of infections imported by migrants and travellers. Preliminary data show the significant presence of transmissible diseases and the potential reintroduction in Spain, as well as the importance of systematic screening in patients that came from tropical areas. The objective of +Redivi is to evaluate the impact of imported diseases in Spain in order to contribute to improving the care of patients, to have an influence on prevention and treatment of the most prevalent imported diseases, and to detect possible outbreaks.
Copyright © 2011 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22409952     DOI: 10.1016/j.eimc.2012.01.026

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN: 0213-005X            Impact factor:   1.731


  5 in total

1.  Usefulness of Strongyloides stercoralis serology in the management of patients with eosinophilia.

Authors:  Fernando Salvador; Elena Sulleiro; Adrián Sánchez-Montalvá; José María Saugar; Esperanza Rodríguez; Albert Pahissa; Israel Molina
Journal:  Am J Trop Med Hyg       Date:  2014-03-10       Impact factor: 2.345

2.  Newly Arrived African Migrants to Spain: Epidemiology and Burden of Disease.

Authors:  Joaquín Salas-Coronas; María Teresa Cabezas-Fernández; Ana Belén Lozano-Serrano; Manuel Jesús Soriano-Pérez; José Vázquez-Villegas; José Ángel Cuenca-Gómez
Journal:  Am J Trop Med Hyg       Date:  2018-01       Impact factor: 2.345

3.  The business traveler. A new high-risk traveler profile?

Authors:  J A Pérez-Molina
Journal:  Rev Clin Esp (Barc)       Date:  2015-08-28

Review 4.  Clinical Spectrum of Schistosomiasis: An Update.

Authors:  Cristina Carbonell; Beatriz Rodríguez-Alonso; Amparo López-Bernús; Hugo Almeida; Inmaculada Galindo-Pérez; Virginia Velasco-Tirado; Miguel Marcos; Javier Pardo-Lledías; Moncef Belhassen-García
Journal:  J Clin Med       Date:  2021-11-25       Impact factor: 4.241

5.  Imported malaria including HIV and pregnant woman risk groups: overview of the case of a Spanish city 2004-2014.

Authors:  María Fernández López; Jose Manuel Ruiz Giardín; Juan Víctor San Martín López; Jerónimo Jaquetti; Isabel García Arata; Carolina Jiménez Navarro; Noemi Cabello Clotet
Journal:  Malar J       Date:  2015-09-17       Impact factor: 2.979

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.